Cellectis Nom Eo 05 News - ALCLS

Monthly information on share capital and company voting rights

Monthly information on share capital and company voting rights (Article 223-16 of General Regulation of the French financial markets...

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (Article 223-16 du Règlement...

Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024

Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024 NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext...

Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing

NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: ...

Cellectis dévoile une approche de thérapie génique non-virale pour traiter la drépanocytose dans Nature Communications

Cellectis dévoile une approche de thérapie génique non-virale pour traiter la drépanocytose dans Nature Communications NEW YORK, 12 juin...

Monthly information on share capital and company voting rights

Monthly information on share capital and company voting rights (Article 223-16 of General Regulation of the French financial markets...

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (Article 223-16 du Règlement...

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia NEW YORK...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Cellectis Nom Eo 05 (ALCLS)

Professional-Grade Tools, for Individual Investors.

ALCLS News

Monthly information on share capital and company voting rights

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024

Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing

Cellectis dévoile une approche de thérapie génique non-virale pour traiter la drépanocytose dans Nature Communications

Monthly information on share capital and company voting rights

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia

ALCLS Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Cellectis Nom Eo 05 (ALCLS) News

Cellectis Nom Eo 05 (ALCLS)

Professional-Grade Tools, for Individual Investors.

ALCLS News

Monthly information on share capital and company voting rights

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024

Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing

Cellectis dévoile une approche de thérapie génique non-virale pour traiter la drépanocytose dans Nature Communications

Monthly information on share capital and company voting rights

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia

ALCLS Discussion

Your Recent History